Additionally, the AOM CRC model resembles human CRC at the molecular level in many respects, including the dysregulated AKT/mTORC pathway (74, 75), which is the dominant target of the VTD-UBXN2A therapeutic approach. This evidence concerns the gene UBXN2A and infectious otitis media.